Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0014118 (endocarditis)
 15,629 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Prosthetic valve endocarditis is an infrequent but serious complication of cardiac valve replacement. The overall frequency of prosthetic valve endocarditis is approximately 2%. The frequency of early-onset and late-onset infections is 0.78% and 1.1%, respectively. Staphylococci are the most common isolate from patients with early-onset infection, accounting for 47.5% of the total number of isolates. Staphylococcus epidermidis causes 27% of these staphylococcal infections. Among patients with late-onset infection, streptococci are the predominant microorganism, constituting 42% of the total number of isolates from patients in this group. The overall mortality among patients with prosthetic valve endocarditis is high--59%; the mortality among patients with early- or late-onset infections is 77% and 46%, respectively. Most patients with staphylococcal prosthetic valve endocarditis should undergo cardiac valve replacement in addition to antimicrobial therapy. Closely monitored anticoagulant therapy should be cautiously continued in patients with prosthetic valve endocarditis.
 ...
PMID:Prosthetic valve endocarditis. 706 79

Cardiac valve replacement was performed in 94 patients (95 operations) in the presence of active infective endocarditis. Most of the patients were extremely ill. The operation was performed as an emergency or semiemergency lifesaving procedure in 88% of them, and more than half received little or no antibiotic treatment prior to the operation. The hospital mortality was 16%--14% for aortic valve replacement (AVR) and 11% for double valve replacement (DVR) but 31% for isolated mitral valve replacement (MVR). The mortality was not higher in patients operated on urgently (emergency or semiemergency), nor was it higher in patients who had aortic annular abscesses or aneurysms. Prosthetic valve endocarditis (PVE) (in each case occurring more than 60 days after the previous valve operation) carried a higher mortality (33%) than native valve endocarditis (NVE) (14%). The relatively high early mortality for MVR may have been related to the fact that we operated upon MVR patients after intensive medical treatment had failed. The late results were good: Sixty-six patients are alive and well, 51 of them in Functional Class I. Six patients were reoperated upon for aortic periprosthetic leaks, and five are now well. Eight patients died late (9%), one of them because of a periprosthetic leak and one because of a clotted valve. In seven of the eight deaths, the cause of death was probably not related to the timing of the original operation. We recommend early valve replacement for patients with infective endocarditis. We believe that early operation reduces mortality, prevents emboli, and is associated with excellent long-term results.
 ...
PMID:Cardiac operation during active infective endocarditis: results of aortic, mitral, and double valve replacement in 94 patients. 712 Oct 47

Prosthetic valve endocarditis (PVE) has been traditionally divided into early (EPVE) and late (LPVE) forms, the division being made at 60 days after operation. Recent actuarial studies suggest that the risk of EPVE continues up to 12 months after operation. This new insight must increase the emphasis on perioperative prevention, including those measures taken at the time of operation, such as antibiotic prophylaxis, and particularly, the prevention of postoperative nosocomial bacteraemia which other recent studies suggest is a much more significant factor than previously appreciated. The application of DNA-based typing methods of the predominant causative organisms of EPVE [coagulase-negative staphylococci; (CNS)] can be increasingly expected to unravel the aetiology of EPVE and support more logical preventive measures. As with the prevention of native valve endocarditis, the prevention of LPVE currently relies on antibiotic prophylaxis at predictable times of bacteraemia. Epidemiological studies have shown that events currently recognized account for a very minor proportion of cases. The elucidation of the incidence, causes and potential preventive measures of the spontaneous bacteraemias responsible for most cases of LPVE remains a major task. The prevention of all forms of PVE is presently inadequate. Recent studies have not improved our abilities but have served to define areas in which existing measures should be re-emphasized and other areas in which more knowledge is urgently required.
 ...
PMID:Prevention of prosthetic valve endocarditis. 756 Sep 82

From March 1978, 196 Carpentier-Edwards standard bioprostheses (stCE) were implanted in 194 patients. There were 154 isolated mitral valve replacements (MVR) and 42 aortic plus mitral valve replacements (AVR/MVR) with a mean follow-up of 7.05 (range 0-15.2) years and 7.15 (range 0-13.8) years, respectively. Freedom from structural valve failure at 10 years was 70.8% +/- 4.9% (MVR) and 59.6% +/- 11.1% (AVR/MVR). The incidence of structural valve failure increased sharply after 7 years. Freedom from thromboembolism was 83.0% +/- 3.8% (MVR) and 89.0 +/- 6.0% (AVR/MVR). Thromboembolic events were related to the presence of atrial fibrillation in patients not receiving anticoagulation. Anticoagulant-related haemorrhage was rare. Freedom from mitral valve prosthetic endocarditis at 10 years was 90.9% +/- 3.1% (MVR) and 86.1% +/- 8.4% (AVR/MVR). Prosthetic valve endocarditis was associated with more than 60% mortality. The probability of event-free survival at 10 years follow-up was 43.6% +/- 4.6% (MVR) and 33.3% +/- 8.6% (AVR/MVR). The performance of the stCE in the mitral position shows a low rate of thromboembolic events and anticoagulant-related haemorrhage, but the long-term performance of the prosthesis is unsatisfactory due to a high rate of structural valve failure. This confirms earlier reports.
 ...
PMID:Mitral valve replacement with the Carpentier-Edwards standard bioprosthesis: performance into the second decade. 766 78

Prosthetic valve endocarditis remains an extremely serious complication, with a low but increasing incidence. 'Late' endocarditis, occurring more than 60 days after surgery, is relatively infrequently associated with staphylococci, Gram-negative bacteria and fungi so characteristic of the endocarditis that occurs earlier. A probable source of infection can be found in 25%-80% of patients, the most frequent causes being dental procedures, urological infections and interventions, and indwelling catheters. The most common organisms are S. epidermidis, S. aureus, viridans streptococci and enterococci. The general principles of antibiotic treatment are similar to those for native valve endocarditis, but antibiotic treatment needs to be more prolonged and dosages should be used which result in maximal, nontoxic concentrations. Oral anticoagulants should be stopped and replaced by intravenous heparins. Surgical reintervention is called for if there are large highly mobile vegetations in the mitral position or within 72 h if there are cerebral thrombo-embolic episodes.
 ...
PMID:Late prosthetic valve endocarditis. 767 23

Prosthetic valve endocarditis is still a very serious complication, carrying an incidence of death between 30 and 70% in some series. Therefore early and accurate diagnosis is crucial. Early (less than 60 days post surgery) endocarditis is usually a fulminant disease, where staphylococcal infection is most common. Late prosthetic endocarditis resembles more closely other forms of the disease. Conventional echocardiography is useful in the evaluation of prosthetic valve function, but it is very limited in the demonstration of infective lesions, primarily because of acoustic shadowing. Transoesophageal echocardiography (TE) enables high resolution imaging of the heart without chest wall interference, and viewing of the heart from the posterior (atrial, low pressure) side, where most of the vegetations are expected to be found in both mitral and tricuspid positions. It also enables better visualization of the left ventricular outflow tract, where aortic prosthetic vegetations tend to be present. Furthermore, transoesophageal echocardiography allows accurate diagnosis of some of the common complications of endocarditis: abscess/cavity formation; mycotic aneurysm; prosthetic valve dehiscence and regurgitation. In spite of these advantages, limitations should be recognized. Struts are commonly seen on transoesophageal echocardiography following surgery and should not be confused with vegetations. Similarly, normal prosthetic regurgitation should not be confused with paravalvar leakage. Nevertheless, transoesophageal echocardiography, when expertly used, changes the possibility for early and more accurate diagnosis of prosthetic valve endocarditis dramatically. Transoesophageal echocardiography should be included among the major criteria in the diagnosis and follow-up of prosthetic valve endocarditis.
 ...
PMID:Echocardiographic assessment of prosthetic valve endocarditis. 767 26

Prosthetic valve endocarditis, which is an uncommon but potentially fatal complication of valve replacement, may result in annular abscess formation (mechanical valves) or primarily leaflet infection (xenografts and homografts). Insertion of a mechanical or xenograft valve in the setting of aortic root infection carries a risk of reinfection, which is highest in the first 4 months after valve replacement. In contrast, the homograft aortic valve does not have this early risk of prosthetic valve endocarditis, but instead a constant and low risk across time. Because of this apparent intrinsic resistance to infection, the aortic homograft valve is the replacement device of choice for prosthetic valve endocarditis. An additional advantage of the homograft aortic valve for prosthetic valve endocarditis is the fact that this device has the flexibility to enable its use even in extensive aortic root destruction, including left ventriculo-aortic discontinuity. The homograft valve can be inserted as a root replacement after excision of the infected aortic root, or as a subcoronary or cylindrical technique for less extensive infection.
 ...
PMID:The impact of aortic valve homografts on the treatment of aortic prosthetic valve endocarditis. 789 34

Prosthetic valve endocarditis is associated with high mortality and morbidity. Although antibiotics alone may sterilize an infected prosthetic valve, adjunctive surgical therapy is often necessary. Depending on the virulence of the offending microorganism, the type of prosthetic valve and the site where it was implanted, the infection spreads into paravalvular structures, producing abscess. Systemic embolization of infected material may cause metastatic abscess. Thus, timing of surgery in these patients is crucial to optimize clinical results. An aggressive approach is justifiable in most patients with prosthetic valve endocarditis. It is believed that radical resection of all infected material and reconstruction of the heart and annuli with fresh autologous or glutaraldehyde-fixed bovine pericardium offer the best chance to eradicate the infection. Prolonged antibiotic therapy is also necessary in these patients. In the author's personal experience with 45 patients with prosthetic valve endocarditis, the infection was limited to the valve in 10 patients and had extended into the surrounding tissues in 35. The operative mortality rate was 13%. The actuarial survival at 5 years was 61% +/- 5%. These results support the premise that radical resection of all infected materials offers a good chance for curing prosthetic valve endocarditis.
 ...
PMID:The surgical treatment of patients with prosthetic valve endocarditis. 789 37

Prosthetic valve endocarditis is a rare complication of valve replacement surgery but carries a grim prognosis. The physiopathology of this condition allows identification of two clinically distinct forms based on their bacteriological profiles and outcome: early endocarditis, diagnosed in the first year following valve replacement is observed in 0.7 to 3% of cases: staphylococci are the predominant organism as contamination usually occurs at operation. The prognosis is poor due to the high incidence of complications and the mortality rate is about 60 to 70%; late endocarditis: diagnosed after the second year, it is observed in 0.5 to 1% of cases per year. Contamination is due to bacteraemia and the commonest organisms are the streptococci. The mortality rate is over 20%. The diagnosis is particularly difficult in chronic forms and those with negative blood cultures. Cardiac imaging in prosthetic valve endocarditis is mainly dependent on Doppler echocardiography especially using the transoesophageal approach which allows evaluation of lesion such as abscesses, vegetations and perivalvular leaks, and enables planning of treatment. Management is medico-surgical. Apart from symptomatic treatment of complications, antibiotic therapy using synergistic drugs at bactericidal dosages intravenously is essential as soon as bacteriological specimens have been sent for culture. Surgery is essential in early forms but may be avoided in uncomplicated late forms. The timing of surgery (the objectives of which are to excise the infected material, to repair destructive lesions and to implant a new valve) is a decisive factor in reducing the morbidity and mortality of this condition. Prophylactic measures have a particularly important role to play: they are based on pre- per- and postoperative guide lines.
 ...
PMID:[Prosthetic valve endocarditis: current problems]. 802 89

Between January 1985 and March 1990, isolated Omnicarbon valve replacement operations were performed on 90 patients aged 25-72 years. There were 53 aortic valve replacements (AVR) and 37 mitral valve replacements (MVR). The cumulative follow-up was 320 patient-years, with a mean(s.d.) follow-up of 3.7(1.4) years. There were three operative and hospital deaths (3.3%) resulting from retrograde aortic dissection during cardiopulmonary bypass, postoperative renal failure and postoperative mediastinitis. Seven patients died during the late postoperative period, four from valve-related causes. Two of these patients died from prosthetic valve endocarditis, and the others died from thromboembolism and valve thrombosis. The mean(s.d.) actuarial survival rate at 6 years was 86.2(4.3)% (98.8(0.8)% for AVR, 82.1(4.8)% for MVR). The mean(s.d.) actuarial survival rate of freedom from all valve-related mortality at 6 years was 93.5(2.6)% (100% for AVR, 88.1(2.9)% for MVR). There were two thromboembolic events (one mesenteric artery thrombosis and one valve thrombosis). The standardized incidence of thromboembolism was 0.63% per patient-year. Prosthetic valve endocarditis occurred in three patients (0.94% per patient-year). One patient (0.31% per patient-year) was found to have a paravalvular leak resulting from aortitis syndrome. The mean(s.d.) actuarial rate of freedom from all valve-related complications at 6 years was 89.2(2.0)% (98.6(1.0)% for AVR, 86.4(2.2)% for MVR). There were no instances of anticoagulant-related haemorrhage, valve-related haemolysis, or structural failure. Results of a follow-up period of 6 years indicated that good clinical results and a low incidence of valve-related complications can be demonstrated with the Omnicarbon valve.
 ...
PMID:Six years' experience with the Omnicarbon valve prosthesis. 807 3


<< Previous 1 2 3 4 5 6 7 8 9 Next >>